-24.30 (-1.91%) Dr. Reddy’s Laboratories and its US subsidiary Promius Pharma LLC have filed New Drug Application (NDA) for its migraine candidate DFN-02 with the US Food and Drug Administration (USFDA).
The filing of DFN-02 NDA represents the company’s continuing commitment to bring innovative solutions in migraine treatment.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.